Symptomatic orthostasis with extended-release nifedipine and protease inhibitors

Pharmacotherapy

Volumn 22, Issue 10, 2002, Pages 1312-1316

  Rossi, Deanna R ^a   Rathbun, R Chris ^b   Slater, Leonard N ^c,d  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b College of Pharmacy ^*  (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPRENAVIR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DICLOFENAC; DIDANOSINE; DIURETIC AGENT; EFAVIRENZ; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LAMIVUDINE; LOSARTAN; NELFINAVIR; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TACROLIMUS; UNINDEXED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRADYCARDIA; CASE REPORT; CORONARY ARTERY DISEASE; DRUG INDUCED DISEASE; HEART BLOCK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOKALEMIA; MALE; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PROTEINASE INHIBITION; SUSTAINED RELEASE PREPARATION; VIRUS INFECTION; CHEMICALLY INDUCED DISORDER; DELAYED RELEASE FORMULATION; DRUG INTERACTION; MIDDLE AGED;

ANTI-HIV AGENTS; ANTIHYPERTENSIVE AGENTS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; NELFINAVIR; NIFEDIPINE; OXAZINES; RITONAVIR;

EID: 0036792835     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.15.1312.33478     Document Type: Article

References (16)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
3. Agouron Pharmaceuticals Inc. Nelfinavir mesylate (Viracept) product information. La Jolla, CA; 2001.
4. Schvarcz R, Rudbeck G, Soderdahl G, Stahle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000;69:2194-5.
5. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000;49:185-9.
6. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45:3445-50.
7. Pfizer Laboratories. Nifedipine extended-release tablets (Procardia XL) product information. New York, NY; 1997.
8. Rosenkranz B, Ledermann H, Frolich JC. Interaction between nifedipine and atenolol. J Cardiovasc Pharmacol 1986;8:943-9.
9. AstraZeneca Pharmaceuticals LP. Atenolol tablets (Tenormin) professional information brochure. Wilmington, DE; 2000.
10. Mark AL. The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol 1983;1:90-102.
11. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
12. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40:51-8.
13. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
14. Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased mdr-1/P glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 1993;268:2946-52.
15. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
16. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999;56:383-9.